Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ESMO 2025 | Metastatic breast cancer updates at ESMO 2025

Janice Wing-Hang Tsang • 17 Oct 2025
ESMO 2025
Breast Cancer Antibodies
VIKTORIA-1

Janice Wing-Hang Tsang, MBBS, MRCP, FRCP, University of Hong Kong, Hong Kong, China, provides an overview of the metastatic breast cancer track at ESMO 2025, including updates from the VIKTORIA-1 trial (NCT05501886), novel antibody-drug conjugates in triple-negative breast cancer, as well as patient-reported outcomes and quality of life data. This interview took place at the European Society for Medical Oncology (ESMO) 2025 Congress in Berlin, Germany.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

More from Janice Wing-Hang Tsang

Highlights from ESMO Breast 2024: addressing toxicities in new cancer treatments
2:15
Highlights from ESMO Breast 2024: addressing toxicities in new cancer treatments
Janice Wing-Hang Tsang • 17 May 2024
13-year follow up results of the SOFT and TEXT trials in ILC
1:56
13-year follow up results of the SOFT and TEXT trials in ILC
Janice Wing-Hang Tsang • 17 May 2024
Assisted reproductive techniques in patients after BRCA-mutant breast cancer
1:55
Assisted reproductive techniques in patients after BRCA-mutant breast cancer
Janice Wing-Hang Tsang • 17 May 2024
Enhancing patient education in breast cancer treatment
3:25
Enhancing patient education in breast cancer treatment
Janice Wing-Hang Tsang • 21 Oct 2023

Related Videos

Phase I trial of neoadjuvant rintatolimod and celecoxib in resectable mCRC
1:20
Phase I trial of neoadjuvant rintatolimod and celecoxib in resectable mCRC
Sarbajit Mukherjee • 1 Jun 2026
CRCI and compromised adjuvant chemotherapy delivery in cancer
5:16
CRCI and compromised adjuvant chemotherapy delivery in cancer
Filippos Koinis • 1 Jun 2026
ASCENT-04: PFS2 with sacituzumab govitecan and pembrolizumab in PD-L1+ mTNBC
1:12
ASCENT-04: PFS2 with sacituzumab govitecan and pembrolizumab in PD-L1+ mTNBC
Kevin Kalinsky • 31 May 2026
Clinical relevance of PFS2 in metastatic triple-negative breast cancer
1:10
Clinical relevance of PFS2 in metastatic triple-negative breast cancer
Kevin Kalinsky • 31 May 2026
The content of VJOncology is intended for healthcare professionals